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• Define Systemic Lupus Erythematosus (SLE) and 
understand it’s clinical manifestations and diagnosis
• Become familiar with the treatment of SLE
• Discuss SLE through the life stages including 
pregnancy counseling and contraceptive use
• Discuss preventative measures for SLE patients
• Develop a better understanding of the role of PCPs 
in the care of SLE patients
INSPIRATIONAL PATIENT 
32-year-old with “no significant PMH” presents to the office to establish care with a routine 
physical exam and would also like to go on birth control.  She is thinking of getting pregnant 
in about a year but would like to be protected until that point.  She otherwise feels fine.  She 
has intermittent pain in her knees and hands, but she takes NSAIDs and it goes away.  She 
has no other complaints.  
You review her history, and she goes “oh and I have lupus, but it doesn’t really bother me”….
WHAT IS SYSTEMIC LUPUS 
ERYTHEMATOSUS? 
• Complex autoimmune disease with wide range of organ involvement
• Course is typically recurrent, with periods of relative remission followed by 
flares
• Prevalence estimated to be 30-50 per 100,000
WHAT CAUSES LUPUS?
• WHO KNOWS
• Triggered in genetically susceptible individuals by exposure to certain 
environmental risk factors
WHY SHOULD I CARE
• SLE patients consult their GP more frequently with relevant clinical features 
during 5-year period prior to diagnosis
• GPs correctly diagnosis on 11% of SLE cases presented in written scenarios
• Compared to the general population patients with SLE have at least a 5-fold 
increase in mortality
• 1/3 of patients lose the ability to work within 5 years after disease onset
DOES EARLIER DIAGNOSIS MATTER?
• Population based screening not advised
• Average time from symptom onset to diagnosis is approximately 2 years
• longer lag time for children, males, and late-onset disease
• Less than 6-month delay may experience lower flare rates, less healthcare 
utilization, and costs than those with at least 6 months
• Failure to achieve low disease activity in first 6 months after diagnosis with 
early damage accrual
WHO GETS LUPUS - KAHOOT
WHO GETS LUPUS?
• Women in their reproductive years
• More common in African Americans, Hispanics, Asian-Americans, Native 
Americans, Native Hawaiians, pacific islanders
• Black women are 3 times more likely to develop lupus than white women
• Affects 1 in 250 black women
• Patients who have relatives with lupus have 5-13% chance of developing 
disease themselves
HEALTH DISPARITIES
• Among Medicaid enrollees across the US from 2000-2004, prevalence of lupus 
and lupus nephritis highest in zip code areas of lower SES
• Racial/ethnic minorities and low-income individuals less likely to receive 
recommended healthcare for lupus
• Poverty associated with higher mortality and variety of poor outcomes
• Low-income individuals less likely to see specialist and likely to have to travel 
significantly further to see one
MOST COMMON PRESENTATION –
KAHOOT
WHEN TO SUSPECT LUPUS
• Can affect any organ
• Not all manifestations appear simultaneously
• Often constitutional symptoms (esp fatigue), mucocutaneous and MSK 
symptoms present the earliest
CLUES ON PHYSICAL EXAM
• Younger age
• African American
• Painless mouth ulcers
• Arthralgias in hands
• Pregnancy complications
• Rash








• Common: fatigue, weight loss, fever without 
focal infection
• In up to 90% patients
• Less common
• Malar rash (31%), photosensitivity (23%), 
pleuritic chest pain (16%), new-onset 
Raynaud phenomenon (16%), mouth 
sores (12.5%)
• Strongest physical evidence that favors SLE
• Discoid rash +LR = 18
• Malar Rash +LR = 14
• Unexplained seizures or psychosis +LR 
= 13




• CBC, TSH, UA
• ANA 
• Low diagnostic specificity
• Confirm specific autoantibodies
• Anti-dsDNA
• Anti-Sm Ab
• No diagnostic criteria
CLASSIFICATION CRITERIA
• 3 sets: 
• American College of Rheumatology (ACR) criteria (1997)
• Systemic Lupus Erythematosus International Collaborating Clinics (SLICC)/ACR 
Criteria (2012)
• European Union League Against Rheumatism/American College of Rheumatology 
Criteria (2019)
• Differ in emphasis placed on various immunologic and clinical domains
(Huang et al, 2018)
E U RO P E A N  U N I O N  L E AG U E  
AG A I N S T  R H E U M AT I S M / A M E R I C A N  
C O L L E G E  O F  R H E U M ATO L O G Y  
C R I T E R I A  ( 2 0 1 9 )
(Fanouriakis et. al, 2019)





• Juvenile idiopathic arthritis





• Viral infections (parvovirus)




TREATMENT – ORGAN SPECIFIC
• Hydroxychloroquine is cornerstone of treatment
• Low dose glucocorticoids used to treat most manifestations




• Protects against development of organ involvement and more severe disease
• Takes several months (about 3) to control symptoms
• 300-400mg/d– for remission consider tapering to 200mg/d
• Retinal toxicity
• Recommend dilated eye exam at baseline, at 5 years of use, and annually after 5 years 
of use
• Should not be dosed more than 5mg/kg due to risk of retinal disease
• Toxicity related to dose and duration of therapy
• Retinal disease found in 1% after 5 years and sharply increases to 20% after 20 years
FLARES AND MONITORING - KAHOOT
MONITORING OF FLARES
• Disease activity: 
• anti-dsDNA
• complements (C3, C4)
• creatinine/RFP
• CBC
• UA/Urine protein analysis 
• Every 3-6 months
• SLEDAI-2K score(Gladman, 2021)
INSPIRATIONAL PATIENT 
32-year-old with “no significant PMH” presents to the office to establish care with a routine 
physical exam and would also like to go on birth control.  She is thinking of getting pregnant 
in about a year but would like to be protected until that point.  She otherwise feels fine.  She 
has intermittent pain in her knees and hands, but she takes NSAIDs and it goes away.  She 
has no other complaints.  
You review her history, and she goes “oh and I have lupus, but it doesn’t really bother me”….
PREGNANCY COUNSELING - KAHOOT
PREGNANCY IN LUPUS
• NOT associated with decreased fertility
• A lot of medications are teratogenic
• Up to 1/3 require C-section
• Up to 1/3 with preterm birth
• Increased risk of Preeclampsia, gestational diabetes mellitus, infection 
• Major risk factors for adverse maternal and fetal outcomes: 
• active/flaring disease (particularly active lupus nephritis)
• history of lupus nephritis
• presence of antiphospholipid Ab/antiphospholipid syndrome
PREGNANCY COUNSELING
• Plan pregnancy – delay conception until at least 6 months remission (6-12m)
• Off risky medications
• Teratogenic: cyclophosphamide, ACEi, ARBs, warfarin, methotrexate, mycophenolate 
mofetil
• Continue important medications: hydroxychloroquine, azathioprine, 
corticosteroids when appropriate
• Low dose ASA
ANTIPHOSPHOLIPID SYNDROME
• Associated with autoantibody having an apparent specificity for negatively charged 
phospholipids with venous thrombosis, arterial thrombosis, and/or pregnancy loss
• Antiphospholipid AB present in 1/3 lupus patients
• 1/3 of those will have ≥1 clinical manifestation
• Consider if 
• ≥1 unexplained death at ≥10 weeks gestation
• ≥ 1 preterm birth (< 34wk gestation) due to severe preE, eclampsia, or placental 
insufficiency





• Anti-Ro and Anti-La
• Cutaneous features: annular erythematous rash
• Often photosensitive
• Transient
• Cardiac disease: 1-3rd degree heart block
• May be permanent and require pacing
(Haebich et al, 2015)
(Sechi et. Al, 2020)
CHILDHOOD SLE
• 15-20% of SLE presents in childhood
• Hormonal influence on presentation (rare <5 yo and 
uncommon before adolescents)
• Disease activity higher in childhood SLE than adult 
SLE at presentation




• 5-15% of all lupus patients
• Still predominantly women, higher percentage whites
• Drug-induced should be ruled out
• Incidence of false positive ANA increases with age
• Characteristics
• Reduced likelihood of proteinuria, cellular casts, and 
seizures
• Reduced prevalence of anti-RNP, anti-Sm, and anti-
dsDNA ab
• Low complement levels
• Lower levels of disease activity
INSPIRATIONAL PATIENT 
32-year-old with “no significant PMH” presents to the office to establish care with a routine 
physical exam and would also like to go on birth control.  She is thinking of getting pregnant 
in about a year but would like to be protected until that point.  She otherwise feels fine.  She 
has intermittent pain in her knees and hands, but she takes NSAIDs and it goes away.  She 
has no other complaints.  






• Frequently have a variety of comorbidities 
• Males have higher rates cardiovascular disease/stroke and cancer
• Female patients have higher rates infection and osteoporosis
• Prevalence:
• Dyslipidemia 36% at diagnosis to 60% after 3 years
• Diabetes 2.7-7% and increases over time to 14%
• Obesity in 1/3 patients
• Most common cause of death in SLE patients
• Heart disease and stroke (1.7x general population)
• Hematologic malignancies and lung cancer (2.1x general 
population)
• Infection (5x general population)
• Renal disease (7.9x general population)
ACCELERATED ATHEROSCLEROSIS
• Atherosclerotic events among leading causes of mortality in lupus patients
• Rate of MI 50-fold higher in 35–44-year-olds
• 1st cardiac event occurs at ≤55 in more than 2/3 patients
• Vasculitis extremely rare
• Control modifiable risk factors: blood pressure, glucose, tobacco exposure, 
cholesterol, sedentary lifestyle at young ages
• EKG and stress test when indicated based on history and exam
• Value of statins tests in RCTs which failed to show clear benefit over placebo
• Low dose ASA may be considered for primary prevention of CVD
PREVENTATIVE MEASURES – SMOKING 
CESSATION
• Smoking triggers SLE onset
• HR 1.86 of more than 10 pack year smoking with SLE risk
• Smoking cessation reduces risk to that of nonsmokers
• Smoking increases cutaneous manifestations, flares, organ damage
• Worse therapeutic results
• Interferes with efficacy of anti-malarials
• Raises pulmonary pressures
• Associated with greater degree of inflammatory arthritis
• Worsens Raynaud's
PREVENTATIVE MEASURES – WEIGHT 
CONTROL
• Increased weight leads to decreased functional capacity, more fatigue, increased 
risk metabolic syndrome
• Physical activity hard secondary to joint pain, osteoporosis, neuropathy but can 
enhance quality of life
• Improved pulmonary function
• Diminishes fatigue
• Increases endurance
• Increased BMI associated with poorer prognosis
PREVENTATIVE MEASURES -
IMMUNIZATIONS
• Pneumococcus and influenza
• Live virus vaccines are contraindicated when patient receiving 
immunosuppressive treatment
• Including prednisolone at dose >20mg/day
• SLE itself is NOT a contraindication
• Avoid in patients on mycophenolate, cyclophosphamide, other immunosuppressive 
medications
• Patients as young as 40 may benefit from herpes zoster vaccines
• Give HPV
PREVENTATIVE MEASURES – BONE 
DENSITY
• Females with lupus are nearly 5x more likely to experience fracture from 
osteoporosis
• Recommend adequate Ca and vitamin D intake and weight bearing activity for 
patient on chronic prednisone
• Vitamin D has been postulated to be an environmental trigger for autoimmune diseases
• ≥3 months of prednisolone (2.5mg/d)
• elemental Ca (1000-1200 mg/d)
• cholecalciferol (600-800 IU/d) 
• Patients on chronic high dose steroids (>20mg prednisone) or with history of 
fractures warrant more aggressive monitoring
PREVENTATIVE MEASURES – CANCER 
SCREENINGS
• Overall risk of cancer 10-15% higher than the general population
• Increased risk of non-Hodgkin’s Lymphoma (3-4x) compared to general 
population
• Lack of studies comparing enhanced cancer screening in lupus patients
• Recommendation for the same screening as the general population
• Potentially enhanced screening for cervical dysplasia/cancer especially in those 
who received high potency immunosuppressive therapy
PREVENTATIVE MEASURES - OTHER
• Sun protection
• SPF 30 absorbs/reflects 97% UV light
• use 30 or above 30 minutes before going out into sun to all exposed body parts 
and reapply after 1-2 hours
• Avoidance of unnecessary sun exposure remains most important behavioral 
modification
• Hats, protective clothing, and umbrellas are blocking
• No evidence for anti-inflammatory diet
WHEN TO REFER
• All SLE patients should have a Rheumatologist
• When physical exam is not suggestive of clinically overt disease and lab tests 
show only isolated low-titer positive ANA
SUMMARY
• SLE is a complex autoimmune disease with a wide spectrum of organ 
involvement and presentation
• Classic presentation is women in reproductive years
• Initial work up: CBC, TSH, UA
• High sensitivity test: ANA
• High Specificity test: anti-dsDNA
• Flares: anti-dsDNA, C3, C4, CBC, Up:cr, UA, RFP
• Treatment: hydroxychloroquine, glucocorticoids, immunosuppressants
SUMMARY
• 6-12m of disease control before pregnancy and need MFM involvement
• Copper IUD is best form of contraception unless severe thrombocytopenia
• Avoid the patch
• SLE patients often have accelerate atherosclerosis
• Preventative measures including: 
• UV protection
• Smoking cessation
• Bone density monitoring
• Immunizations
• Cancer screenings
• Blood pressure, lipid, BMI monitoring
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